Gene editing and modulation for Duchenne muscular dystrophy
Copyright © 2021 Elsevier Inc. All rights reserved..
Duchenne muscular dystrophy (DMD) is a progressive muscle disease caused by loss of dystrophin protein, encoded by the DMD gene. DMD manifests early in childhood as difficulty walking, progresses to loss of ambulation by the teens, and leads to death in early adulthood. Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation have emerged, making great strides in uncovering barriers to gene therapies for DMD and other genetic diseases. While this first-generation of DMD therapies are being evaluated in ongoing clinical trials, uncertainties regarding durability and therapeutic efficacy prompted the development of new experimental therapies for DMD that take advantage of somatic cell gene editing. These experimental therapies continue to advance toward clinic trials, but questions remain unanswered regarding safety and translatable efficacy. Here we review the advancements toward treatment of DMD using gene editing and modulation therapies, with an emphasis on those nearest to clinical applications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:182 |
|---|---|
| Enthalten in: |
Progress in molecular biology and translational science - 182(2021) vom: 24., Seite 225-255 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stephenson, Anthony A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adeno-associated virus |
|---|
| Anmerkungen: |
Date Completed 25.11.2021 Date Revised 25.11.2021 published: Print-Electronic ClinicalTrials.gov: NCT04601051 Citation Status MEDLINE |
|---|
| doi: |
10.1016/bs.pmbts.2021.01.029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327221186 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327221186 | ||
| 003 | DE-627 | ||
| 005 | 20231225200311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/bs.pmbts.2021.01.029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327221186 | ||
| 035 | |a (NLM)34175043 | ||
| 035 | |a (PII)S1877-1173(21)00040-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stephenson, Anthony A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gene editing and modulation for Duchenne muscular dystrophy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.11.2021 | ||
| 500 | |a Date Revised 25.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04601051 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a Duchenne muscular dystrophy (DMD) is a progressive muscle disease caused by loss of dystrophin protein, encoded by the DMD gene. DMD manifests early in childhood as difficulty walking, progresses to loss of ambulation by the teens, and leads to death in early adulthood. Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation have emerged, making great strides in uncovering barriers to gene therapies for DMD and other genetic diseases. While this first-generation of DMD therapies are being evaluated in ongoing clinical trials, uncertainties regarding durability and therapeutic efficacy prompted the development of new experimental therapies for DMD that take advantage of somatic cell gene editing. These experimental therapies continue to advance toward clinic trials, but questions remain unanswered regarding safety and translatable efficacy. Here we review the advancements toward treatment of DMD using gene editing and modulation therapies, with an emphasis on those nearest to clinical applications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adeno-associated virus | |
| 650 | 4 | |a DMD | |
| 650 | 4 | |a Dystrophin | |
| 650 | 4 | |a Exon skipping | |
| 650 | 4 | |a Gene therapy | |
| 650 | 7 | |a Dystrophin |2 NLM | |
| 650 | 7 | |a Oligonucleotides, Antisense |2 NLM | |
| 700 | 1 | |a Flanigan, Kevin M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progress in molecular biology and translational science |d 2008 |g 182(2021) vom: 24., Seite 225-255 |w (DE-627)NLM18554178X |x 1878-0814 |7 nnns |
| 773 | 1 | 8 | |g volume:182 |g year:2021 |g day:24 |g pages:225-255 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/bs.pmbts.2021.01.029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 182 |j 2021 |b 24 |h 225-255 | ||